Inhibikase Therapeutics Inc (IKT) — Cash Flow Reinvestment Rate

Latest as of September 2020: 0.00x

Inhibikase Therapeutics Inc (IKT) has a Cash Flow Reinvestment Rate of 0.00x as of September 2020, reinvesting $0.00 (capex $0.00 ) from operating cash flow of $75.52K. Explore Inhibikase Therapeutics Inc (IKT) cash flow conversion to assess how effectively this company generates cash.

Reinvestment Rate

0.00x

(Capex + Investments) / Operating CF

Total Reinvested

$0.00

Capex + Investments

Operating Cash Flow

$75.52K

USD

Capital Expenditures

$0.00

USD

Inhibikase Therapeutics Inc Cash Flow Reinvestment Rate (2018–2018)

Historical reinvestment intensity for Inhibikase Therapeutics Inc across 1 annual periods. Explore Inhibikase Therapeutics Inc cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.

Annual Cash Flow Reinvestment Rate for Inhibikase Therapeutics Inc (2018–2018)

Year-by-year capital reinvestment analysis for Inhibikase Therapeutics Inc. For live market cap and broader valuation context, see market value of Inhibikase Therapeutics Inc.

Year	Reinvestment Rate	Total Reinvested (USD)	Operating CF	Capex	YoY Change
2018	0.12x	$87.10K	$714.99K	$0.00	—

Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow